Climb Bio (CLYM) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.18

Estimate

-$0.21

Surprise

+15.3%

Score today

5.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Climb Bio (CLYM) reported a narrower loss than forecast — diluted EPS of -$0.18 against the -$0.21 estimate (a 15.3% beat on a still-unprofitable quarter).

TrendMatrix currently rates CLYM Sell at 5.9/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +15.3% surprise compares with a -1.6% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$13.87

Price target

$19.89

Stop

$13.38

Upside to target

+43.4%

Reward-to-risk

2.5:1

Model outputs from TrendMatrix’s engine as of 2026-09-03 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$864.4M

P/E (fwd)

-14.4

52-week range

$1.54–$18.33

Off 52-week high

24.3%

RSI (14)

40

Volume vs avg

1.52×

Score today

5.9/10